Use of sodium polystyrene sulfonate for reduction of plasma lithium concentrations after chronic lithium dosing in mice.
OBJECTIVE
Previous studies have shown that oral sodium polystyrene sulfonate lowers plasma lithium concentrations after acutely administered oral doses of lithium chloride. However, a significant proportion of lithium overdose cases resulting in morbidity and mortality are those in which exposure to lithium is chronic. This study was designed to determine whether multiple oral doses of sodium polystyrene sulfonate are effective in reducing plasma lithium concentrations after chronic dosing.


METHODS
Placebo-controlled animal study.


METHODS
One hundred thirty mice were given 75 mM lithium chloride in their drinking water for a period of 14 days. At the end of that period, half of the animals were given orogastric sodium polystyrene sulfonate at 5 g/kg/dose 0, 60, 120, 180, and 360 minutes after the cessation of lithium chloride; the remaining half received orogastric water at equivalent times. Subgroups of each group were sacrificed at 90, 150, 330, 480, 1440, and 2880 minutes after lithium chloride cessation and plasma analyzed for lithium content. Lithium concentrations were compared by analysis of variance and single degree of freedom contrasts. Significance was set at an alpha level of 0.05.


RESULTS
Lithium concentration was lower overall in the animals treated with sodium polystyrene sulfonate (p < .0001) and specifically at 150, 330, and 480 minutes after lithium chloride cessation (p < .05).


CONCLUSIONS
Repetitive oral doses of sodium polystyrene sulfonate effectively lowered plasma lithium concentrations. Further study may ultimately define a role for the use of sodium polystyrene sulfonate in the treatment of patients with chronic lithium toxicity.
Linakis
J G
JG
Rhode Island Hospital, Providence 02903, USA. James_Linakis_PhD@brown.edu
Savitt
D L
DL
Wu
T Y
TY
Lockhart
G R
GR
Lacouture
P G
PG
D000284:Administration, Oral; D000818:Animals; D062787:Drug Overdose; D008094:Lithium / Q000097:blood*; D018021:Lithium Chloride / Q000633:toxicity*; D008297:Male; D051379:Mice; D011041:Poisoning / Q000097:blood / Q000188:drug therapy*; D011137:Polystyrenes / Q000494:pharmacology*; D011897:Random Allocation; D016896:Treatment Outcome
D011137:Polystyrenes; C003321:polystyrene sulfonic acid; D008094:Lithium; D018021:Lithium Chloride